View all news

Recent Hologic Acquisition Bolder Surgical Included on Fast Company's Annual List of World's Most Innovative Companies


--Company Recognized for Pioneering Advanced Energy Vessel Sealing Surgical Devices, 
Including Hologic's CoolSeal® Vessel Sealing Portfolio--

MARLBOROUGH, Mass. March 10, 2022 – Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health, announced today that recently acquired Bolder Surgical was included on Fast Company's annual list of the World's Most Innovative Companies. Bolder Surgical, a developer and manufacturer of advanced energy vessel sealing and dissection tools for surgical gynecologists in both laparoscopic and open procedures, was acquired by Hologic in November 2021.

Bolder ranked fifth on the list of Most Innovative Medical Device Companies, a sector highlighting companies that are creatively using technology to improve patient care. The full list of Most Innovative Companies consisted of 528 companies chosen by a team of editors and reporters for Fast Company from thousands of applicants across the globe.

“We're thrilled that Bolder — the newest member of our Surgical business — has captured a spot on Fast Company's prestigious list of the most innovative companies making an impact around the globe,” said Essex Mitchell, Hologic’s Division President, Surgical. “The CoolSeal devices have already proven to be an important addition to our growing Surgical portfolio, and we're looking forward to seeing how we can continue to improve efficiency for surgeons and hospitals, while helping to improve outcomes for patients, through these innovative products.”

Bolder was recognized for its innovation in designing surgical devices, in particular the CoolSeal® devices, which allow for dissection, vessel sealing and dividing all-in-one tool. The ability to use a combination device improves surgical efficiency by reducing the need for instrument exchanges. In addition, Bolder’s CoolSeal® Mini 3 mm vessel sealer and the JustRight® 5 mm stapler are designed for small surgical spaces such as in pediatric cases, which can help reduce the need for larger, overpowered instruments.

Hologic’s surgical product line also includes the NovaSure® endometrial ablation system for the treatment of abnormal uterine bleeding, the MyoSure® tissue removal devices for the removal of intrauterine fibroids and polyps, the Acessa® laparoscopic radiofrequency ablation system for the treatment of fibroids, and the Fluent® fluid management system for streamlining hysteroscopic procedures.

According to Fast Company, the Most Innovative Companies list “has been the definitive source for recognizing the organizations that are transforming industries and shaping society” since it began in 2008.

About Hologic, Inc. 

Hologic, Inc. is a medical technology innovator primarily focused on improving women’s health and well-being through early detection and treatment. Its advancements include invention of 3D mammography to fight breast cancer; leadership in testing for cervical cancer, sexually transmitted infections, respiratory illnesses and the virus that causes COVID-19; and minimally invasive surgical technologies for uterine fibroids and abnormal uterine bleeding. The Company also champions women through the Hologic Global Women’s Health Index, which provides a science-backed data roadmap for improving women’s well-being, and Project Health Equality, which elevates awareness, research insights and access to quality care for underserved women. For more information on Hologic, visit

Hologic, Acessa, CoolSeal, Fluent, JustRight, MyoSure and The Science of Sure are trademarks and/or registered trademarks of Hologic, Inc., and/or its subsidiaries in the United States and/or other countries. 

Forward-Looking Statements 

This news release may contain forward-looking information that involves risks and uncertainties, including statements about the use of Hologic products. There can be no assurance these products will achieve the benefits described herein or that such benefits will be replicated in any particular manner with respect to an individual patient, as the actual effect of the use of the products can only be determined on a case-by-case basis. In addition, there can be no assurance that these products will be commercially successful or achieve any expected level of sales. Hologic expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such data or statements are based. 

This information is not intended as a product solicitation or promotion where such activities are prohibited. For specific information on what products are available for sale in a particular country, please contact a local Hologic sales representative or write to

Media Contact: 
Jane Mazur

Vice President, Corporate Communications 
508.263.8764 (direct) 
585.355.5978 (mobile) 


Investor Contact: 
Ryan Simon 
Vice President, Investor Relations 
858.410.8514 (direct)  

Multimedia Files:

View all news